Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS)
KL Neuhaus,
U Tebbe,
M Gottwik,
MA Weber,
W Feuerer,
W Niederer,
W Haerer,
F Praetorius,
KD Grosser,
W Huhmann,
et al.
Medizinische Klinik II, Staedtische Kliniken Kassel, West Germany.
The effects of recombinant tissue plasminogen activator (rt-PA) and urokinase on patency and early reocclusion of infarct-related coronary arteries were investigated in a single blind, randomized multicenter trial in 246 patients with acute myocardial infarction of less than 6 h duration. Both 70 mg of single chain rt-PA with an initial bolus of 10 mg and 3 million units of urokinase with an initial bolus of 1.5 million units were given intravenously over 90 min. The first angiographic study at the end of the infusion revealed a patent infarct-related artery (Thrombolysis in Myocardial Infarction trial [TIMI] grade 2 or 3) in 69.4% of 121 patients given rt-PA versus 65.8% of 117 patients given urokinase (p = NS). Among patients treated within 3 h from symptom onset a patent infarct-related artery was found in 63.9% of 72 patients given rt-PA versus 70% of 70 patients given urokinase (p = NS). There were five cardiac deaths in each group and one fatal intracranial hemorrhage in the rt-PA group. The in-hospital reinfarction rate was 8.9% versus 13.2% for patients treated with rt-PA and urokinase, respectively. There was no difference in left ventricular function at baseline and follow-up catheterization studies. Both drugs were well tolerated and there was no significant difference in cardiovascular or bleeding complications between the two groups. It is concluded that rt-PA and urokinase in the dosages used provide similar efficacy and safety in the treatment of acute myocardial infarction. Reocclusion during the first 24 h may be less frequent after urokinase treatment.
This article has been cited by other articles:
|
|
|
|
 
E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy
Intravenous Thrombolysis in Acute Myocardial Infarction
Chest,
January 1, 2001;
119(1_suppl):
253S - 277S.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Iqbal, H. Messmore, D. Hoppensteadt, J. Fareed, and W. Wehrmacher
State-of-the-Art Review : Thrombolytic Drugs in Acute Myocardial Infarction
Clinical and Applied Thrombosis/Hemostasis,
January 1, 2000;
6(1):
1 - 13.
[PDF]
|
|
|
|
|
|
|
C. Sillaber, M. Baghestanian, D. Bevec, M. Willheim, H. Agis, S. Kapiotis, W. Fureder, H. C. Bankl, H. P. Kiener, W. Speiser, et al.
The Mast Cell as Site of Tissue-Type Plasminogen Activator Expression and Fibrinolysis
J. Immunol.,
January 15, 1999;
162(2):
1032 - 1041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Maki, C. Shirato, M. Ohguchi, N. Aoki, N. Ochiai, S. Taguchi, I. Aoki, and K. Ishikawa
Mechanism of Rethrombosis After Thrombolytic Therapy: Angioscopic Findings and Investigation of the Coagulation System in Dogs
Angiology,
June 1, 1998;
49(6):
447 - 453.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Goto, Y. Kawai, S. Abe, E. Takahashi, S. Handa, S. Ogawa, K. Watanabe, S. Hori, and Y. Ikeda
Serial Changes in Coagulant Activities After Thrombolytic Therapy for Acute Myocardial Infarction
Angiology,
April 1, 1994;
45(4):
273 - 281.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. W. Krichbaum and D. A. Trivedi
Thrombolytic Therapy in Acute Myocardial Infarction
Journal of Pharmacy Practice,
January 1, 1990;
3(5):
332 - 348.
[PDF]
|
|
|
|
|
|
|
ARE CLOT-SPECIFIC THROMBOLYTIC AGENTS BETTER?
Journal Watch (General),
September 6, 1988;
1988(906):
3 - 3.
[Full Text]
|
|
|
|
